Previous Close | 244.77 |
Open | 244.06 |
Bid | 247.10 x 800 |
Ask | 247.20 x 900 |
Day's Range | 243.01 - 247.63 |
52 Week Range | 198.64 - 258.45 |
Volume | |
Avg. Volume | 3,164,396 |
Market Cap | 139.408B |
Beta (5Y Monthly) | 0.59 |
PE Ratio (TTM) | 25.51 |
EPS (TTM) | 9.70 |
Earnings Date | Apr 25, 2022 - Apr 29, 2022 |
Forward Dividend & Yield | 7.76 (3.19%) |
Ex-Dividend Date | May 16, 2022 |
1y Target Est | 249.25 |
Novartis (NVS) Cosentyx gets a positive CHMP recommendation for the indication of juvenile idiopathic arthritis.
J&J's immunology mega-blockbuster loses exclusivity in the U.S. next year -- and Amgen's biosimilar is ready to capitalize.
Mirati (MRTX) seeks a nod for its lung cancer candidate adagrasib in the European Union. A regulatory filing in the United States is currently under the FDA review with decision pending this year-end.